Generated record revenue of approximately $120 million for full-year 2025, driven by PAC performance Reported Adjusted EBITDA(1) of $13 million, representing 26% improvement year-over-year Provided ...
BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidatesBioNTech co-founders Ugur Sahin and Özlem Türeci will est ...
To maintain its supply logistics amid disrupted supply chains around the Persian Gulf, the company leverages its extensive global trading and chartering network. According to Senior Vice President ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results